Tesaro Takes Lead: Ovarian Cancer PhIII Pushes Niraparib Ahead Of Clovis' PARP Inhibitor

 
• By Lucie Ellis-Taitt
  
Racing horse
Tesaro's drug has the potential to overtake AstraZeneca's approved PARP inhibitor Lynparza • Source: Shutterstock/Ogla-i
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

More from Scrip